DeepMed Research

Perphenazine

Generic Name: Perphenazine

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆ClN_₃OS

CAS Number: 58-39-9

Unique Ingredient Identifier: FTA7XXY4EZ

Background: An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

Indication: For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Associated Conditions: Anxiety, Depression, Schizophrenia, Moderate Agitation, Moderate Anxiety, Moderate Depressed mood, Severe Anxiety, Severe Depressed mood, Severe Nausea and vomiting, Severe agitation

Clinical Trials

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

Phase 2

Recruiting

Conditions: Ischemic Stroke, Acute

Interventions: Drug: Riociguat
Drug: Propylthiouracil
Drug: Perphenazine

First Posted Date: 2023-03-09

Last Posted Date: 2023-10-19

Lead Sponsor: Maastricht University

Target Recruit Count: 28

Registration Number: NCT05762146

Locations: 🇩🇪
University Hospital Essen, Department of Neurology, Essen, Germany

Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers

Phase 1

Completed

Conditions: Safety Issues
Drug Drug Interaction

Interventions: Drug: Propylthiouracil, Riociguat, Perphenazine

First Posted Date: 2021-03-01

Last Posted Date: 2022-04-04

Lead Sponsor: Maastricht University

Target Recruit Count: 8

Registration Number: NCT04776499

Locations: 🇩🇪
UniversitätsKlinikum Heidelberg - Medizinische Klinik, Heidelberg, Germany

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

Phase 3

Recruiting

Conditions: Perioperative Optimization

Interventions: Drug: Neuraxial Analgesia
Drug: Perphenazine
Drug: Ondansetron 4 MG
Drug: Aprepitant
Drug: Dimenhydrinate
Drug: Dexamethasone

First Posted Date: 2020-10-28

Last Posted Date: 2024-10-08

Lead Sponsor: Jennifer Holder-Murray

Target Recruit Count: 2500

Registration Number: NCT04606264

Locations: 🇺🇸
UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC Passavant, Pittsburgh, Pennsylvania, United States

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed

Conditions: Schizophrenia

Interventions: Other: Caregiver psycho-education and skills training
Other: Caregiver support available at the study site
Drug: Paliperidone palmitate
Drug: Chlorpromazine
Drug: Droperidol
Drug: Fluphenazine
Drug: Haloperidol
Drug: Loxapine
Drug: Perphenazine
Drug: Pimozide
Drug: Prochlorperazine
Drug: Thiothixene
Drug: Thioridazine
Drug: Trifluoperazine
Drug: Aripiprazole
Drug: Asenapine
Drug: Clozapine
Drug: Iloperidone
Drug: Olanzapine
Drug: Paliperidone
Drug: Quetiapine
Drug: Risperidone
Drug: Ziprasidone

First Posted Date: 2015-11-09

Last Posted Date: 2019-01-23

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 296

Registration Number: NCT02600741

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Phase 3

Completed

Conditions: Schizophrenia
Psychotic Disorders

Interventions: Drug: Paliperidone Palmitate Injection (PP1M)
Drug: Aripiprazole
Drug: Paliperidone Palmitate Injection (PP3M)
Drug: Haloperidol
Drug: Olanzapine
Drug: Oral Paliperidone ER
Drug: Perphenazine
Drug: Quetiapine
Drug: Oral Risperidone

First Posted Date: 2015-05-01

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 337

Registration Number: NCT02431702

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Phase 4

Completed

Conditions: Schizophrenia and Disorders With Psychotic Features
Schizoaffective Disorders
Schizophrenia

Interventions: Drug: Olanzapine
Drug: Amisulpride
Drug: Risperidone
Drug: Haloperidol
Drug: Quetiapine
Drug: Perphenazine
Drug: Sulpiride
Drug: bromperidol
Drug: Zuclopenthixol
Drug: Thioridazine
Drug: Paliperidone
Drug: Ziprasidone
Drug: Benperidol
Drug: Fluspirilene
Drug: Pimozide
Drug: Perazine
Drug: Fluphenazine
Drug: Flupentixole
Drug: Sertindole

First Posted Date: 2014-12-04

Last Posted Date: 2018-10-11

Lead Sponsor: Technical University of Munich

Target Recruit Count: 21

Registration Number: NCT02307396

Locations: 🇩🇪
Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Lurasidone
Drug: Haloperidol
Drug: Perphenazine

First Posted Date: 2014-07-24

Last Posted Date: 2021-03-01

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 35

Registration Number: NCT02199743

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Phase 4

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: haloperidole
Drug: perphenazine
Drug: paliperidone palmitate
Drug: olanzapine
Drug: paliperidone
Drug: aripiprazole
Drug: risperidone
Drug: quetiapine

First Posted Date: 2010-09-01

Last Posted Date: 2013-07-08

Lead Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC

Registration Number: NCT01193166

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy